menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Inke Achieves Aprepitant CEP and Salmeterol DMF A Step Forward

    PRESS RELEASE

    GSK to cap out-of-pocket inhaler costs in US

    REUTERS

    Drugmakers benefit `substantially` from secondary patents on inhalers — study

    ENDPTS

    Enforcement Report- Week of October 27, 2021

    FDA

    Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler®

    BLOOMBERG

    Cipla submits application with USFDA for generic version of asthma drug

    ECONOMICTIMES

    Cipla share price up 8% on successful completion of Ph-3 study of asthma drug

    MONEYCONTROL

    Teva announces FDA approval of ArmonAir Digihaler inhalation powder

    NJBIZ

    GSK leans on respiratory franchise with Trelegy share-grab

    FIERCE PHARMA

    FDA knocks back AstraZeneca`s respiratory ambitions

    BIOPHARMADIVE

    Charging at blockbuster Advair, Novartis boasts topline victories

    ENDPTS

    Product Hopping: E&C Hearing Addresses Restrictions to Generic Competition

    RAPS

    New respiratory drugs, Shingrix help GSK weather Advair generics

    FIERCE PHARMA

    AstraZeneca’s COPD triplet Breztri nabs first nod from Japan

    FIERCE PHARMA

    GSK pharma head flags need for speed in high-pressure drug market

    REUTERS

    Novartis` asthma triplet beats GSK`s Advair in phase 2 trial

    FIERCE BIOTECH

    Mylan investors are fed up with management, analysts say

    FIERCE PHARMA

    Generic Advair hits GSK revenues hard

    BIOPHARMADIVE

    Biotech shares continue to fall on FDA uncertainty

    CNBC

    Mylan`s Advair generic pressures GSK with strong launch

    BIOPHARMADIVE

    Mylan shares sink as bleak profit outlook sparks growth concerns

    CNBC

    UBS strips GSK of ‘buy’ recommendation on fears for its ViiV HIV division

    PROACTIVE INVESTOR

    Mylan`s generic Advair discount not as big as it looks: analysts

    FIERCE PHARMA

    FDA draft lays out submission paths for combo products

    MEDTECH DRIVE

    Hal Barron’s GSK team continues to cull resp drugs in big shift to oncology R&D

    ENDPTS

    Mylan Wins FDA Approval for First Advair Generic

    RAPS

    FDA approves first generic Advair Diskus

    FDA

    GSK about to see Mylan’s generic carve into its mega-blockbuster Advair franchise

    ENDPTS

    Vectura sinks after PhIII asthma trial ends in failure, marking another setback

    ENDPTS

    That generic Advair you`ve been expecting for months? It`ll come, Mylan says

    FIERCE PHARMA

    Mylan`s Beat Lifts Hopes That Worst Is Over for Generic Drugs

    BLOOMBERG

    GlaxoSmithKline expands API production for COPD inhalers

    FIERCE PHARMA

    Mylan reveals its $463M mystery buy - Novartis` TOBI cystic fibrosis products

    FIERCE PHARMA

    AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    PMLIVE

    Hit by surprise setback, AZ explains why inhaler beaten by GSK rival

    ENDPTS

    GSK chief rounds out her top team with CFO pick — but performance lags

    ENDPTS

    Drugs for heart failure are still under-prescribed, years after initial study

    SCIENCE DAILY

    What`s in the Cards for Glaxo This Earnings Season?

    NASDAQ

    Mylan preps for rejection of Advair copy

    REUTERS

    UPDATE 2-FDA finds deficiencies in Mylan`s generic Advair; shares fall

    CNBC

    Mylan CEO`s EpiPen defense reverberates in pricing debate

    FIERCE PHARMA

    Glaxo`s Advair Is the $100 Billion Asthma Drug That Won`t Die

    BLOOMBERG

    GSK pharma boss rejigs operations to double down on launches

    FIERCE PHARMA

    New Hikma CEO Olafsson gets to work on 200 more generics layoffs

    FIERCE PHARMA

    FDA sends Hikma back to the clinic with generic Advair

    FIERCE PHARMA

    GSK escapes Advair hit for now as second generic bid fails

    REUTERS

    Novartis` Advair copy stiff-armed at FDA, giving GSK a reprieve

    FIERE PHARMA

    GlaxoSmithKline sees light at end of Advair tunnel

    REUTERS

    The decade`s top 10 patent losses, worth a whopping $915B in lifetime sales

    FIERCE PHARMA

    Hikma Pharma trims guidance as generic Advair talks continue with FDA

    SHARE CAST

    Mylan points finger at FDA for missing Advair, Copaxone copies

    FIERCE PHARMA

    Valeant prices psoriasis treatment at $3,500 per month (April 21)

    REUTER

    6 Biotechs Facing Key FDA Decisions in March

    BIOSPACE

    Federal Judge Blocks Anthem’s Planned Acquisition of Cigna

    WALL STREET JOURNAL

    GSK books solid results on weak pound, new products

    PHARMATIMES

    How does GSK`s incoming chief view the Advair generic threat?

    FIERCE PHARMA

    Bernie Sanders: Will Trump have the guts to stand up to drug companies?

    WASHINGTON POST

    AirDuo steps up to challenge Advair, but the newcomer`s fate depends on price

    FIERCE PHARMA

    FDA Approves Two Teva Asthma Treatments

    GLOBES

    Cipla gets UK nod to sell key inhaler for asthmatics

    BUSINESS STANDARD

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.